Vendor Intelligence Report: Hunan GoodPeptides Biotech Co

Executive summary

Across 3 Finnrick lab tests, GoodPeptides is 3 pass / 0 fail for an overall pass rate of 100%. The clean signal is real but narrow: every Finnrick result in the supplied record is Tirzepatide, making that the only GoodPeptides product with direct Finnrick support. Retatrutide and Cagrilintide may appear in the public catalog, but they do not inherit confidence from the Tirzepatide record.

The identity record is stronger than the manufacturing record. The report ties Hunan GoodPeptides to a Zhuzhou parent entity, named ownership records and both Zhuzhou and Changsha addresses; the chronology fits a 2022 export-brand launch more than an independently verified long-running pharmaceutical manufacturer. Investigators did not locate public GMP/ISO certificates, factory-inspection proof, a signed COA verification portal or an anti-counterfeit batch lookup.

The domain map is the other major buyer signal. goodpeptides.com remained active, but older sister-site links were removed from the footer while several connected domains were expired, unreachable, empty or dropped; one former steroid-linked domain was observed for sale. That creates an authenticity problem for buyers using off-site sellers or old bookmarks rather than the canonical storefront.

Regulatory risk is product-specific, not a blanket purity verdict. Searches did not surface a direct FDA warning letter naming GoodPeptides, but the GLP-1 and steroid footprint sits in a higher-enforcement lane: FDA materials cited in the report flag Retatrutide and Cagrilintide compounding limits, and Import Alert 66-80 exposure remains relevant for U.S. GLP-1 shipments.

Inside the full report:

• Appendix A lab breakdown for the single tested product, with rating trajectory and methodology-divergence charts
• Corporate exhibits covering the Zhuzhou parent, ownership trail and address record
• Sister-domain map showing footer-link removals, expired SSL, unreachable sites and a dropped steroid domain
• Regulatory matrix for FDA GLP-1 statements, Import Alert 66-80, CBP seizure context and steroid-catalog risk
• Promotion/reputation scan of @rosepeptides, @goodpeptidescom, Reddit, LinkedIn and YouTube dead ends

Risk assessment

• Product-quality uncertainty outside Tirzepatide — high: Finnrick has only Tirzepatide coverage (3 tests, 3 pass / 0 fail; 81.47%); Retatrutide, Semaglutide, BPC-157, TB-500, HGH, steroids, Cagrilintide and CagriSema are untested in Finnrick data.
• GLP-1 / weight-loss regulatory and border-interdiction risk — high: GoodPeptides lists GLP-1 / weight-loss products including Tirzepatide and Retatrutide; FDA materials flag unapproved GLP-1s and GoodPeptides is not on the Import Alert 66-80 Green List, leaving U.S. GLP-1 API shipments exposed to DWPE.
• Steroid-catalog legal and customs risk — high: ChemicalBook lists 77 steroid products under GoodPeptides; this category is controlled/restricted in many buyer jurisdictions and can elevate seizure, payment and legal risk independent of peptide quality.
• Operational traceability and domain-control risk — medium: Former/connected domains were removed from the footer, expired, unreachable or dropped (goodsteroid.com for sale; steroidpep.com/npeptides.com unreachable) without a current official-channel list or anti-counterfeit system.
• Manufacturing-provenance verification gap — medium: Records show a Zhuzhou office/registry address and Changsha marketing address, but no public GMP/ISO/factory-verification or signed COA verification portal was located.